Tests IMVT-1402 in adults with generalized myasthenia gravis
Tests the drug IMVT-1402 against placebo in adults with generalized myasthenia gravis.
Plain-language title generated from the registry record
Registry title: Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Key facts
- Where
- Atlanta, Augusta, Carlsbad, Chapel Hill, Charleston, Charlottesville, Cincinnati, Clearwater, Dallas, Denton, Detroit, Durham, East Lansing, Eugene, Fort Collins, Foxborough, Greenfield, Houston, Huntsville, Irvine, Lexington, Los Angeles, Lubbock, Memphis, Mobile, New Haven, New Orleans, New York, Nicholasville, Oklahoma City, Omaha, Ormond Beach, Phoenix, Port Charlotte, Raleigh, Rancho Mirage, Richmond, Rockledge, San Francisco, Schaumburg, Scottsdale, Tampa, Totowa, Tucson, Washington D.C., and Yukon, United StatesSee the 48 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07039916, who can take part
Where in United States
- AtlantaAtlanta, United StatesTaking people
- AugustaAugusta, United StatesTaking people
- CarlsbadCarlsbad, United StatesTaking people
- Chapel HillChapel Hill, United StatesTaking people
- CharlestonCharleston, United StatesTaking people
- CharlestonCharleston, United StatesTaking people
- CharlottesvilleCharlottesville, United StatesTaking people
- CincinnatiCincinnati, United StatesTaking people
- ClearwaterClearwater, United StatesTaking people
- DallasDallas, United StatesTaking people
- DentonDenton, United StatesTaking people
- DetroitDetroit, United StatesTaking people
- DurhamDurham, United StatesTaking people
- East LansingEast Lansing, United StatesTaking people
- EugeneEugene, United StatesTaking people
- Fort CollinsFort Collins, United StatesTaking people
- FoxboroughFoxborough, United StatesTaking people
- GreenfieldGreenfield, United StatesTaking people
- HoustonHouston, United StatesTaking people
- HuntsvilleHuntsville, United StatesTaking people
- IrvineIrvine, United StatesTaking people
- LexingtonLexington, United StatesTaking people
- Los AngelesLos Angeles, United StatesTaking people
- LubbockLubbock, United StatesTaking people
- MemphisMemphis, United StatesTaking people
- MobileMobile, United StatesTaking people
- New HavenNew Haven, United StatesTaking people
- New OrleansNew Orleans, United StatesTaking people
- New YorkNew York, United StatesTaking people
- New YorkNew York, United StatesTaking people
- NicholasvilleNicholasville, United StatesTaking people
- Oklahoma CityOklahoma City, United StatesTaking people
- OmahaOmaha, United StatesTaking people
- Ormond BeachOrmond Beach, United StatesTaking people
- PhoenixPhoenix, United StatesTaking people
- Port CharlottePort Charlotte, United StatesTaking people
- RaleighRaleigh, United StatesTaking people
- Rancho MirageRancho Mirage, United StatesTaking people
- RichmondRichmond, United StatesTaking people
- RockledgeRockledge, United StatesTaking people
- San FranciscoSan Francisco, United StatesTaking people
- SchaumburgSchaumburg, United StatesTaking people
- ScottsdaleScottsdale, United StatesTaking people
- TampaTampa, United StatesTaking people
- TotowaTotowa, United StatesTaking people
- TucsonTucson, United StatesTaking people
- Washington D.C.Washington D.C., United StatesTaking people
- YukonYukon, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Immunovant Sciences GmbH
- Trial code
- NCT07039916EU 2024-515979-35-00
- Record updated
- 30 July 2026
- Original description
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.Read full original descriptionShow less
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Inclusion: Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures; Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at the Screening Visit; Have an MG activities of daily living (MG-ADL) score of ≥ 6 at the Screening Visit and Baseline Visit (Day 1); Additional inclusion criteria are defined in the protocol.
Exclusion: Have experienced myasthenic crisis within 12 weeks prior to the Screening Visit; Have had a thymectomy performed < 6 months prior to the Screening Visit or have a planned thymectomy during the study; Have any active or untreated malignant thymoma; Additional exclusion criteria are defined in the protocol.